Related Experiment Video

Updated: Aug 17, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Targeted therapy: for kids, too

Seth J Corey1

  • 1Division of Pediatrics, UT-MD Anderson Cancer Center, Houston, TX 77030, USA. sjcorey@mdanderson.org

Pediatric Blood & Cancer
|February 11, 2005
PubMed

Insights

Signal transduction inhibitor (STI) therapy, or targeted therapy, shows promise for treating pediatric cancers. This approach requires identifying specific molecular targets within tumors for tailored treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy has historically cured pediatric cancers but was not developed for children.
  • New strategies are needed to improve outcomes in pediatric oncology.
  • Current advancements include gene therapy, immunotherapy, and signal transduction inhibitor (STI) therapy.

Purpose of the Study:

  • To review the critical steps in the pre-clinical development of targeted therapy for pediatric cancers.
  • To highlight the potential of STI therapy in pediatric oncology.
  • To emphasize the need for pediatric oncologists to understand molecular signaling pathways.

Main Methods:

  • Review of pre-clinical development steps for targeted therapy.
  • Discussion of signal transduction pathways as drug targets.
  • Examples from pediatric oncology cases.

Main Results:

  • Signal transduction inhibitor (STI) therapy, also known as targeted therapy, is a promising strategy for pediatric cancers.
  • Successful STI therapy requires identification of relevant molecular targets and development of suitable drugs.
  • Tailoring therapy based on a patient's tumor molecular profile is crucial.

Conclusions:

  • Targeted therapy offers a biologically driven approach to treating pediatric cancers.
  • Pediatric oncologists require enhanced understanding of molecular signaling pathways.
  • Further development of STI therapy is essential for advancing pediatric cancer treatment.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.